The trial enrolled a total of twenty-three patients (sixteen with pleural and seven with peritoneal mesothelioma), out of which eleven had a BAP1 mutation (eight somatic and four germline), and one had both somatic BAP1 and germline MRE11A mutations. The gene discussed is BAP1; the disease is peritoneal mesothelioma.